遵守多学科瘤委员会的决定决定了肝细胞癌患者的长期生存率
Robert Oehring1,2, Fabian Jänick1,3, Sharlyn S T Ng1
1Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt- Universität zu Berlin, Chirurgische Klinik CCM/CVK, Augustenburger Platz 1, 13353 Berlin, Deutschland.
Annals of surgery
|September 22, 2025
概括
坚持肝胆多学科瘤委员会 (MDT) 的建议显著改善了肝癌患者的生存率. 患者的偏好和医生的决定也会影响结果,需要考虑.
科学领域:
- 肝胆瘤学 肝胆瘤学
- 癌症治疗决策的制定过程.
- 临床结果研究研究的临床结果.
背景情况:
- 多学科瘤委员会 (MDTs) 对于癌症护理至关重要,指导治疗开始.
- 有限的数据存在于MDT建议的坚持率及其对患者存活率的影响.
研究的目的:
- 评估遵守肝胆道MDT建议对患者结果的影响.
- 确定不遵守MDT建议的原因.
- 为了估计粘附对肝细胞癌 (HCC) 患者的生存的影响.
主要方法:
- 在肝胆MDT中呈现的HCC病例的回顾性单中心研究.
- 从图表审查和临床癌症注册 (2014-2018) 中收集的数据.
- 坚持被分类为主要,次要或不坚持;生存分析.
主要成果:
- 基于患者的90.2%遵守MDT建议 (72.2%主要,18.0%次要).
- 坚持 (4.7年) 与不坚持 (1.5年) 的平均整体存活时间 (mOS) 显着更长.
- 伴随性疾病,瘤进展,患者偏好和医生的决定是偏差的主要原因.
结论:
- 坚持MDT建议与改善HCC患者的长期存活率密切相关.
- 患者的偏好和医生的决定,与瘤因素一起,影响生存,应该得到尊重.
- 优化对MDT计划的坚持可以提高肝癌护理中的患者结果.
更多相关视频
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K


